Joint bookrunners Goldman Sachs and J.P. Morgan assist with financing
By Devika Patel
Knoxville, Tenn., Nov. 8 - Zeltiq Aesthetics, Inc. priced a $58.5 million secondary sale of stock with an $8.78 million greenshoe on Nov. 7, according to a prospectus supplement filed Friday with the Securities and Exchange Commission.
The company will sell 4.5 million common shares at $13.00 apiece. The price per share is a 9.53% discount to the Nov. 6 closing share price of $14.37.
Goldman Sachs & Co. and J.P. Morgan are the joint bookrunning managers.
Settlement is expected Nov. 14.
The Pleasanton, Calif., company's CoolSculpting device offers a non-invasive treatment as an alternative to liposuction.
| Issuer: | Zeltiq Aesthetics, Inc.
|
| Issue: | Common shares
|
| Amount: | $58.5 million
|
| Greenshoe: | $8,775,000
|
| Shares: | 4.5 million
|
| Price: | $13.00
|
| Warrants: | No
|
| Bookrunners: | Goldman Sachs & Co. and J.P. Morgan
|
| Co-managers: | Canaccord Genuity and William Blair
|
| Pricing date: | Nov. 7
|
| Settlement date: | Nov. 14
|
| Stock symbol: | Nasdaq: ZLTQ
|
| Stock price: | $14.37 at close Nov. 6
|
| Market capitalization: | $579.66 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
